IP Library › Granted Patent US 9,061,045
Granted Patent B2
US 9,061,045 · App. 13/533,908 · Granted Jun 23, 2015

Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF

Inventors: Geneviève Choquet-Kastylevsky (Francheville, FR); Yohann Demont (Lille, FR); Hubert Hondermarck (Villeneuve d'Ascq, FR)
Assignees: BIOMERIEUX; UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE
A61K31/713G01N33/57415G01N2333/48A61K38/177A61K39/39558
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,061,045
App. No.
13/533,908
Granted
Jun 23, 2015
Kind
B2
Abstract

A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer.

Claims (16)

1. A method for treating breast, thyroid, lung, or prostate cancer, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a nerve growth factor precursor (ProNGF) inhibitor to a patient having breast, thyroid, lung, or prostate cancer, wherein the ProNGF inhibitor is an siRNA that decreases expression of ProNGF or a ProNGF receptor.

2. The method as claimed in claim 1 , wherein the amount is effective for blocking cancer cell migration or invasion in the patient.

3. The method as claimed in claim 1 , wherein the ProNGF inhibitor specifically penetrates into cancer cells of the patient.

4. A method of inhibiting invasion or migration of cancer cells that produce and secrete nerve growth factor precursor (ProNGF), comprising providing a ProNGF inhibitor to the cancer cells to inhibit the invasion or migration of the cancer cells, wherein the ProNGF inhibitor is an siRNA that decreases expression of ProNGF or a ProNGF receptor.

5. The method as claimed in claim 1 , wherein the method is for treating breast cancer.

6. The method as claimed in claim 1 , wherein the siRNA decreases the expression of Sortilin.

7. The method as claimed in claim 1 , wherein the siRNA decreases the expression of ProNGF.

8. The method as claimed in claim 4 , wherein the cancer cells are breast, thyroid, lung, or prostate cancer cells.

9. The method as claimed in claim 4 , wherein the cancer cells are breast cancer cells.

10. The method as claimed in claim 4 , wherein the siRNA decreases the expression of Sortilin.

11. The method as claimed in claim 4 , wherein the siRNA decreases the expression of ProNGF.

12. A method of inhibiting proliferation of cancer cells that produce and secrete nerve growth factor precursor (ProNGF) in a patient, comprising administering a pharmaceutical composition comprising an effective amount of a ProNGF inhibitor to the patient to inhibit proliferation of the cancer cells, wherein the ProNGF inhibitor is an siRNA that decreases expression of ProNGF or a ProNGF receptor.

13. The method as claimed in claim 12 , wherein the patient has breast, thyroid, lung, or prostate cancer.

14. The method as claimed in claim 12 , wherein the patient has breast cancer.

15. The method as claimed in claim 12 , wherein the siRNA decreases the expression of Sortilin.

16. The method as claimed in claim 12 , wherein the siRNA decreases the expression of ProNGF.

Priority Claims (1)
FR 06 00851 · Jan 31, 2006 · national
Continuity (3)
Continuation 13137101 · Jul 20, 2011
Division 12087606
Related Publication 20130171173A1 · Jul 4, 2013